Literature DB >> 35933566

Clinical interventions to break the obesity and cancer link: a narrative review.

Nakul J Bhardwaj1, Kacey Chae1, Jennifer Y Sheng2, Hsin-Chieh Yeh3.   

Abstract

Excess body weight is a significant risk factor for the development and recurrence of many types of cancer. Patients with a history or current diagnosis of cancer who are overweight or have obesity have an increased risk of cancer treatment-related morbidity, recurrence, and decreased quality of life. Weight loss and maintenance of a healthy body weight may reduce cancer morbidity and recurrence in cancer survivors. While guidelines for cancer survivorship elaborate sufficiently on lifestyle interventions, little guidance is provided when considering additional therapies like anti-obesity pharmacotherapy or bariatric surgery for weight loss. This review will highlight and address current recommendations and feasible interventions that clinicians may consider to further reduce the incidence and recurrence of cancer in patients with obesity.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anti-obesity medication; Bariatric surgery; Cancer; Obesity; Weight loss

Mesh:

Year:  2022        PMID: 35933566     DOI: 10.1007/s10555-022-10055-1

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.237


  1 in total

1.  Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.

Authors:  Pamela J Goodwin; Bingshu E Chen; Karen A Gelmon; Timothy J Whelan; Marguerite Ennis; Julie Lemieux; Jennifer A Ligibel; Dawn L Hershman; Ingrid A Mayer; Timothy J Hobday; Judith M Bliss; Priya Rastogi; Manuela Rabaglio-Poretti; Som D Mukherjee; John R Mackey; Vandana G Abramson; Conrad Oja; Robert Wesolowski; Alastair M Thompson; Daniel W Rea; Paul M Stos; Lois E Shepherd; Vuk Stambolic; Wendy R Parulekar
Journal:  JAMA       Date:  2022-05-24       Impact factor: 157.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.